Divergence Labs

Divergence Labs develops new medicines by combining molecular engineering, machine learning and high-throughput biological experimentation.

Its Cambridge research team integrates antibody and biologics discovery, cell engineering and automated screening to identify and optimise therapeutic candidates. Proprietary hardware and computational models support work across multiple disease areas.

Founded in 2025, the company has disclosed early-stage programmes targeting geographic atrophy, macular telangiectasia and glaucoma.